OCULAR Q3 2026 RESULTS - OCULAR THERAPEUTIX INC

Explicit Guidance:

• No formal quantitative financial guidance (revenue, earnings, margins, capex, cash flow, share count, dividends, or buybacks) was provided for any period.
• Runway: Management stated the company has sufficient cash to extend into 2028 based on current assumptions, excluding the full anticipated expenses of commercializing X-Paxley.

Business-Segment Outlook:

• Wet AMD (Primary Focus):
  • NDA Submission: Planned submission for X-Paxley (OTX-TKI) for wet AMD in the fourth quarter of 2026.
  • Approval Timeline: No specific FDA decision date provided, but management expresses high confidence in approval based on a single trial (SOL1) supported by a comprehensive safety package.
  • SOLAR Trial (Phase 3):
    • Primary Endpoint: Shifted from Week 56 to Week 40 to protect trial integrity and align with safety unmasking requirements for the Q4 NDA.
    • Topline Results: Scheduled for Q1 2028.
    • Secondary Endpoints: Will retain analysis at Week 56 and Week 96 (2 years) to evaluate superiority against aflibercept 8mg and long-term outcomes (fibrosis/atrophy prevention).
    • Safety Submission: Interim safety analysis at Week 52 for SOLAR will be included in the Q4 NDA to meet FDA requirements for 300 patients with one year of follow-up.
  • SOLAR Design: Incorporates a six-month pre-randomization screening to exclude patients with early persistent fluid or variability, aiming to de-risk the efficacy profile.
  • SOLAR Masking: Study remains masked through Week 96.
• SOLX Study (Long-term Extension):
  • Dosing Cadence: Interval extended from 24 weeks to 48 weeks (annual dosing) to generate evidence supporting once-yearly maintenance treatment.
  • Objective: Evaluate if sustained VEGF suppression and earlier initiation reduce fibrosis and atrophy and improve long-term visual outcomes.
• Diabetic Retinal Disease:
  • Helios 3 (Phase 3): Enrollment ongoing for non-proliferative diabetic retinopathy (NPDR) and non-central involving diabetic macular edema.
  • Strategy: Focus on once-yearly dosing for diabetic retinal disease.
  • Update Timing: Expect further details on the diabetic retinopathy strategy in 2027.

Market and Competitive Outlook:

• Treatment Paradigm Shift: X-Paxley is positioned as a long-term maintenance therapy (covering >90% of the wet AMD treatment market) rather than a competitor to bolus anti-VEGF therapies used for initial disease control.
• Competitive Landscape: Management asserts no direct late-stage intravitreal sustained-release competitor remains following the recent discontinuation of a peer TKI program in wet AMD.
• Market Access: Payer discussions completed with 100% of top priority tier national/regional accounts (covering ~84% of commercial lives), showing strong interest in fewer injections and superior durability.
• Labeling Expectations: Anticipates the first and only superiority label for a sustained-release agent, potentially enabling premium pricing and avoiding step-edit requirements.
• Pricing Strategy: Plans to leverage durability and superiority to support premium pricing.

Macro / Industry Outlook:

• Regulatory Pathway: Pursuing approval via the 505(b)(2) pathway to potentially shorten review time by up to 60 days compared to a traditional 505(b)(1) NDA.
• FDA Alignment: Confirmed alignment with the FDA regarding the submission package, the 505(b)(2) pathway, and the protocol changes to SOLAR (endpoint shift and masking).

Strategic Initiatives:

• Board Composition Change: Dr. Riyadh Sharif joined the board to prioritize commercial expertise; Dr. Sung-Se Hong retiring at year-end.
• Commercial Infrastructure: Investing in launch readiness to support rapid physician adoption and broad patient access upon potential approval.
• Clinical Roadmap: Establishing a clinical treatment flow where patients use bolus therapies for initial drying, then transition to X-Paxley for maintenance.
• Capacity/Supply: No specific supply chain announcements, but focus is on preparing infrastructure for "day one" commercialization.

Risks and Headwinds to Outlook:

• Regulatory/Statistical Risk: The shift of the SOLAR primary endpoint from Week 56 to Week 40 incurs a minimal statistical alpha penalty of 0.0001, though management views the new endpoint as well above FDA minimum requirements (36 weeks).
• Operational Risk: Management emphasized the need to protect trial integrity to avoid questions of operational bias during the unmasking process.
• Commercial Execution Risk: Full commercialization expenses have not yet been included in the current cash runway calculation.
• Safety: While safety data is extensive (>300 patients with >1 year follow-up in the NDA package), the drug remains investigational and unapproved.
• Market Adoption Risk: Potential for physician hesitation regarding transition from bolus to maintenance therapies, though market research indicates strong interest.

Management Tone on the Future:

• Confidence Level: Extremely high. Management describes 2026 as "extraordinary," the company's "strongest position in 20-year history," and expresses certainty that X-Paxley will be approved.
• Sentiment: Optimistic and transformative. Phrases used include "never been greater opportunity," "unprecedented confidence," and "laser focused."
• Differentiation: Strong emphasis on TKI potency, delivery vehicle, and rigorous trial design as the keys to outperforming competitors.

Miscellaneous:

• Clinical Evidence: Post-hoc SOL1 analysis shows ~70% of patients remained "quantitatively dry" (≤10 nanoliters fluid) at Week 36 following a single injection.
• Patient Selection: SOLAR pre-randomization screening excluded ~20% of eligible patients due to early persistent fluid, mirroring historical non-inferiority trial failures.
• SOL1 Durability: Approximately two-thirds of patients in the challenging SOL1 population remained rescue-free at 12 months with a single injection.